布洛芬与安慰剂对超级马拉松急性肾损伤影响的随机对照试验
多地点随机双盲安慰剂对照试验在戈壁、阿塔卡马、厄瓜多尔和斯里兰卡沙漠的50英里(80 km)徒步赛中进行,比较布洛芬(每4小时400 mg)与安慰剂对急性肾损伤发生率的影响,非劣效界值定为15%。共纳入89名参赛者(布洛芬组47%,安慰剂组53%),总急性肾损伤发生率为44%。意向治疗分析显示布洛芬组22例(52%)发生急性肾损伤,安慰剂组16例(34%),差异18%(95%CI -4%至41%),OR 2.1(95%CI 0.9至5.1),需伤害人数为5.5。布洛芬组急性肾损伤严重程度更高(风险类别38% vs 26%;损伤类别14% vs 9%),但置信区间均跨0。作者认为耐力跑期间服用非甾体抗炎药可能加重肾损伤,应慎重考虑。
要点
- 50英里(80 km)沙漠超马中,布洛芬组急性肾损伤发生率52%(22例)vs 安慰剂组34%(16例),OR 2.1(95%CI 0.9至5.1),差异18%(95%CI -4%至41%),未达统计学显著但需伤害人数为5.5。
- 布洛芬组急性肾损伤严重程度更高:风险类别38% vs 26%(95%CI -9%至34%),损伤类别14% vs 9%(95%CI -10%至21%),置信区间均跨0。
- 完赛速度较慢者急性肾损伤风险更低(OR 0.67,95%CI 0.47至0.98),体重下降幅度更大(-1.3%)与急性肾损伤风险升高相关(OR 1.24,95%CI 1.00至1.63)。
- 作者认为耐力跑期间服用非甾体抗炎药可能加重肾损伤,摄入前应慎重考虑。
适用人群与场景
- 参加50英里(80 km)徒步赛的超级马拉松跑者,赛事地点为戈壁、阿塔卡马、厄瓜多尔和斯里兰卡沙漠。
诊断标准与关键阈值
- 急性肾损伤定义为肌酐较基线升高1.5倍(风险类别)或2倍(损伤类别),合并计算终点线时总发生率。
- 非劣效界值为急性肾损伤发生率差异15%。
处置流程与药物剂量
- 布洛芬组:每4小时口服布洛芬400 mg,比赛中使用。
研究设计与关键结果
- 多地点随机双盲安慰剂对照试验,纳入89名参赛者(布洛芬组47%,安慰剂组53%),两组人口学特征相似。
- 总急性肾损伤发生率为44%;意向治疗分析:布洛芬组22例(52%)vs 安慰剂组16例(34%)发生急性肾损伤,差异18%(95%CI -4%至41%),OR 2.1(95%CI 0.9至5.1),需伤害人数5.5。
- 急性肾损伤严重程度:风险类别布洛芬组38% vs 安慰剂组26%(95%CI -9%至34%);损伤类别布洛芬组14% vs 安慰剂组9%(95%CI -10%至21%)。
- 完赛速度较慢者急性肾损伤风险更低(OR 0.67,95%CI 0.47至0.98);体重下降幅度更大(-1.3%)与急性肾损伤风险升高相关(OR 1.24,95%CI 1.00至1.63)。
证据类型、等级与局限
- 证据类型:多地点随机双盲安慰剂对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,耐力跑期间摄入非甾体抗炎药可能加重肾损伤,摄入前应慎重考虑。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Despite concerns that non-steroidal anti-inflammatory drugs (NSAIDs) contribute to acute kidney injury (AKI), up to 75% of ultramarathon runners ingest these during competition. The effect of NSAID on AKI incidence in ultramarathon runners is unclear.
METHODS: Multisite randomised double-blind placebo-controlled trial in the Gobi, Atacama, Ecuador and Sri Lankan deserts to determine whether ibuprofen (400 mg every 4 hours) would be non-inferior to placebo during a 50-mile (80 km) foot race. The primary outcome was incidence of AKI defined as severity categories of 'risk' of injury of 1.5× baseline creatinine (Cr) or 'injury' as 2× Cr, combined to calculate total incidence at the finish line. Non-inferiority margin for difference in AKI rates was defined as 15%.
RESULTS: Eighty-nine participants (47% ibuprofen and 53% placebo) were enrolled with similar demographics between groups. The overall incidence of AKI was 44%. Intent-to-treat analysis found 22 (52%) ibuprofen versus 16 (34%) placebo users developed AKI (18% difference, 95% CI -4% to 41%; OR 2.1, 95% CI 0.9 to 5.1) with a number needed to harm of 5.5. Greater severity of AKI was seen with ibuprofen compared with placebo (risk=38% vs 26%; 95% CI -9% to 34%; injury=14% vs 9%; 95% CI -10% to 21%). Slower finishers were less likely to encounter AKI (OR 0.67, 95% CI 0.47 to 0.98) and greater weight loss (-1.3%) increased AKI (OR 1.24, 95% CI 1.00 to 1.63).
CONCLUSION: There were increased rates of AKI in those who took ibuprofen, and although not statistically inferior to placebo by a small margin, there was a number needed to harm of 5.5 people to cause 1 case of AKI. Consideration should therefore be taken before ingesting NSAID during endurance running as it could exacerbate renal injury.
TRIAL REGISTRATION NUMBER: NCT02272725.
参考来源
- Lipman GS, Shea K, Christensen M, et al. Ibuprofen versus placebo effect on acute kidney injury in ultramarathons: a randomised controlled trial. Emerg Med J. 2017. PMID: 28679502. doi:10.1136/emermed-2016-206353
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。